ADC Therapeutics Secures $60 Million Through Private Placement Financing for Growth

On October 13, 2025, ADC Therapeutics SA (NYSE: ADCT), a leading company in the development of antibody drug conjugates (ADCs), announced a significant financial move that could bolster its future operations. The company has entered into securities purchase agreements to raise $60 million through a private placement. This strategic initiative involves selling 11.3 million shares at $4.00 each, alongside pre-funded warrants to purchase an additional 3.8 million shares at $3.90 each. The venture includes participation from reputable investors like TCGX and Redmile Group.

Financial Impact and Objectives

The anticipated gross proceeds of approximately $60 million will serve multiple purposes, including strengthening the company's balance sheet and investing in the commercial expansion of its flagship product, ZYNLONTA®, while also addressing working capital needs. Ameet Mallik, the CEO of ADC Therapeutics, expressed optimism about this development, noting that it enhances the company's capacity to prepare for the potential relaunch of ZYNLONTA in 2027. It further solidifies the company's financial standing, extending its cash runway into 2028.

As of September 30, 2025, ADC Therapeutics reported net product revenues from ZYNLONTA estimated at $15.8 million and cash and cash equivalents totaling $234.7 million. After accounting for the expected net proceeds from the private placement, the company estimates having around $292.3 million in liquid assets.

About ZYNLONTA®

ZYNLONTA® (loncastuximab tesirine-lpyl) is an innovative treatment that specifically targets CD19, a protein commonly found on the surface of B-cell malignancies. Upon binding to CD19-expressing cells, ZYNLONTA is internalized, leading to effective cancer cell destruction through a unique and potent payload. This drug has been approved for use in adult patients diagnosed with relapsed or refractory large B-cell lymphoma, following failure of two or more systemic therapies. The FDA granted ZYNLONTA accelerated approval, while the European Medicines Agency has provided conditional approval based on its overall response rate.

In clinical trials, ZYNLONTA has been shown to be effective even in complicated cases, including those patients who have not responded to previous treatments, highlighting its potential as a leading option for B-cell malignancies. The drug is not only pivotal for existing patients but is also being evaluated in combination studies for use in earlier stages of therapy, thus expanding its therapeutic applications.

Future Outlook

Amidst fluctuating market conditions, ADC Therapeutics remains committed to advancing its proprietary ADC technology and optimizing its product offerings. With the upcoming data catalysts expected later this year and through 2026, the company and its stakeholders are poised to navigate the next phases of growth effectively. As they aim for sustainable long-term development, ADC Therapeutics plans to leverage the funds from the recent financing to enhance its existing products and explore new market opportunities.

ADC Therapeutics operates primarily from Lausanne, Switzerland, and has additional offices in London and New Jersey. The company remains focused on transforming treatment paradigms for patients suffering from hematologic malignancies and solid tumors.

This latest funding round marks a pivotal moment in ADC Therapeutics' journey as it seeks to create a lasting impact in the field of oncology. After successfully navigating through first approvals and building a solid portfolio, ADC is strategically placed to lead innovations in antibody drug conjugates, ultimately providing critical therapies to those in need.